Quantum Genomics — Share Issue/Capital Change 2015

Aug 24, 2015

Regulated information

Paris, august 24th, 2015

Disclosure of the total number of voting rights and the number of shares of the share capital

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has published information on the total number of voting rights and number of shares comprising the share capital on august 23rd 2015, in accordance with the provisions of article 223- 16.

Date	Number of shares	Number of voting rights
August 23rd 2015	6,927,334	Theoretical	8,187,326
		Exercisable(1)	8,163,991

(1) The total number of voting rights is calculated based on the total shares minus shares without voting rights treasury shares. On august 23rd 2015, 23,335 shares, representing a total of 23,335 voting rights, were registered under the liquidity contract assigned to the brokerage Invest Securities.

CONTACTS

Quantum Genomics

jmmarmillon@actus.fr

Lionel Ségard Chairman & Chief Executive Officer 01 60 13 76 80

Quantum Genomics Marc Karako CFO – Investor Relations 01 60 13 76 84 marc.karako@quantum-genomics.com

ACTUS finance et communication Jean-Michel Marmillon Press Relations 01 53 67 36 73

ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

-1-